JW Pharmaceutical announced in a regulatory filing on February 2 that its provisional operating profit for last year reached 93.63 billion won, a 13.5% increase compared to the previous year's operating profit of 82.49 billion won.


During the same period, sales amounted to 774.8 billion won, up 7.7% from 719.38 billion won in the previous year, while net profit for the year decreased by 5.15% to 61.69 billion won.



The company explained that the main factors behind the changes in its profit structure, including operating profit, were increased sales driven by focused development of key products such as Livaro and Livarozet, and a decrease in net profit for the year due to additional corporate tax payments.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing